The number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

A MOTHER has revealed that she has lost 10 and a half stone after using Mounjaro.  Becca Banks, a mum-of-one from the UK, ...

Mounjaro and Zepbound are Eli Lilly's largest ... While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what ...

Meghan Trainor has given the type 2 diabetes drug Mounjaro a special shout out when addressing her recent weight loss ...

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Amy Schumer endorses the new weight loss drug Mounjaro, praising its effectiveness after an adverse experience with Wegovy.

Many employers are facing challenges in incorporating high-cost GLP-1 medications, such as Mounjaro, Ozempic, Rybelsus, Trulicity, and Wegovy, ...

Early adopters of GLP-1 drugs have now lost the weight and are beginning to transition off them. How can F&B support the ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

As it stands today, Mounjaro is Lilly's largest source of revenue ... price tends to move based on investor sentiment around the GLP-1 operation. However, Lilly has several other market-leading ...